Fumagillin treatment recapitulated the effect of metap2 knockdown. (A) WISH comparing expression of mpo between control and fumagillin-treated embryo at 18 hpf (control, 92.8% ± 1.0% with normal mpo expression in total 69 embryos; fumagillin treatment, 69.5% ± 2.5% with increased mpo expression in total 59 embryos; n = 3). (B) WISH comparing expression of c-myb between control and fumagillin-treated embryo at 36 hpf (control, 94.1% ± 1.5% in total 101 embryos with normal c-myb expression; fumagillin treatment, 78.7% ± 3.9% in total 108 embryos with reduced c-myb expression; n = 3). (C) WISH comparing expression of c-myb between control and fumagillin-treated embryo at 48 hpf (control, 94.2% ± 1.5% in total 103 embryos with normal c-myb expression; fumagillin treatment, 75.7% ± 2.4% in total 107 embryos with reduced c-myb expression; n = 3). (D) WISH comparing expression of c-myb (control, 93.1% ± 2.8% in total 102 embryos with normal c-myb expression; fumagillin treatment, 73.0% ± 4.3% in total 89 embryos with reduced c-myb expression; n = 3) and rag1 (red arrow; control, 90.2% ± 1.1% in total 112 embryos with normal rag1 expression; fumagillin treatment, 78.3% ± 2.9% in total 106 embryos with reduced rag1 expression; n = 3) between control and fumagillin-treated embryo at 96 hpf. (E) Confocal microscopy of Tg(fil1:gfp) at 48 hpf comparing the development of dorsal aorta (DA), dorsal vein (DV), and intersegmental vessel (ISV) in the trunk region between control and fumagillin treated embryo (control, 96.6% ± 1.3% in total 116 embryos with normal ISV patterning; fumagillin treatment, 70.3% ± 3.4% in total 118 embryos with perturbed ISV patterning; n = 3). Bars represent 250 μm unless otherwise stated.